Sun, Nov 23, 2014, 1:20 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

jetmanbash 244 posts  |  Last Activity: 14 minutes ago Member since: Dec 29, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jetmanbash jetmanbash 14 minutes ago Flag

    More good news has come out of ISIS in three weeks than vicl in three years. If you guys want to remain head strong that is OK, but you would serve yourself and families better if you just bought ISIS stock and changed your affiliation. Probably won't happen, but I will recheck with you as time goes on and see if you were able to make that difficult decision. In the meantime the VNN will continue to broadcast the decline of your company. t

  • jetmanbash jetmanbash 27 minutes ago Flag

    It is easy to go against you and your imaginary friends and it will become easier and easier. Stick with the stale prune juice thing, won't change a thing. I would buy RNN and sell your vicl to help salvage some kind of retirement besides the trailer park and drinking vodka mixed with prune juice all day. t

  • jetmanbash jetmanbash 29 minutes ago Flag

    You just don't get it. It is not what a company did in the past that will define it. It is what it will do in the future. vicl will however have a negative on both accounts. My biggest wonder is that after vicl goes BK what company will you and the fellas choose as the contender against ISIS? t

  • jetmanbash jetmanbash 32 minutes ago Flag

    I am not mad. I feel very comfortable. My average price for ISIS is below $9 per share. I explained how you miniature Putin's are trying to get false info through. The biggest thing is that the vicl is only 9 cents below the low for the year. ISIS about $11 from the high for the year. vicl has really second rate technology and they don't have a way to dig themselves out of the hole. Now if you want to continue to promote prune juice and this second rate technology from vicl that is OK, a lot of people like the Cubs too. t

  • jetmanbash jetmanbash 36 minutes ago Flag

    I'll try and post the highlights of the last CC tomorrow if I get a chance. To me the company is doing what it can to hit on all cylinders. By the first quarter of 2015 we will know where the company is going and I think the prospects for it going up are really good. t

  • Reply to

    Phase IV for juxta:

    by jetmanbash Nov 21, 2014 12:12 AM
    jetmanbash jetmanbash Nov 21, 2014 11:33 PM Flag

    Hey Dude, is it the truth or is it not? t

  • A review of the most recent charts comparing the total return between ISIS and vicl brought up by numbers-challenged vicl supporter shows that vicl did win the one day chart as of today. They however have lost the 5 day, one month, three months, six months, one year, two year, five year, max. date, and the year to date charts. VNN did learn that the chartist from vicl is leaving that career is going to free-lance and try and rewrite a modern version of Alice in Wonderland. t

  • jetmanbash jetmanbash Nov 21, 2014 10:41 PM Flag

    VNN noting vicl is only 8 cents above the low for the year. Here at the network we are starting to take donations for the workers. They won't get any turkey for Thanksgiving even though their CEO is one. VNN offered to hire a clown to come in and cheer everyone up and they said it wouldn't work the already one. We are trying to relocate some of them to other biotechs. Apparently a lot of them want to work at ISIS but they don't have the skills. Will keep the waiting public on top of this conundrum. t

  • jetmanbash by jetmanbash Nov 21, 2014 12:12 AM Flag

    Re: Two years later and with a head start as the Clara Pela would say, 'where's the beef Mr. juxta?"
    Is it time for the FDA to look into pulling juxta from the market? I think it is very close. The data that comes in for juxta should be considered Phase IV data. The drug was approved conditionally based on future studies. It got a free pass because there was nothing else when it was first approved. Well we know from two years straight data that Mipo does what it is supposed to do and IMO does it convincingly with a trend that is IMO remarkable based on the known very poor prognosis in this particular population. Does juxta have such data? I don't think so. If the drug doesn't work as intended, may cause damage, and there is another product out the that does work for a much cheaper price I think that juxta should be demoted like the antibiotic Trovan was to where the FDA puts further restrictions on its use. In other words, only under really extreme circumstances should the drug even be used at all, or if ever if it can not support CV event reduction. Dr. Beer will probably be wrong again in regards to approval in Germany....it was only a formality(according to him) before the drug received approval in Germany? Don't think so. The public should be protected, where is the efficacy data at the two year mark with a way more than the 23 patient study in regards to how the drug performs in the real world?

    Addendum to above: If there is no such data to support the indication for the drug as intended the price at most should be $1000 per month....actually on the high side but it is a wounded orphan drug after all. t

  • If you want to get a stock quote you only have to use your left hand!! t

  • Two years later and with a head start as the Clara lady would say, 'where's the beef Mr. juxta?"
    The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management
    Current Atherosclerosis Reports, 11/20/2014 Clinical Article

    Ahmad Z, et al. – The data suggest that the cardiovascular benefit of MTP inhibition remains unclear. However, microsomal transfer protein (MTP) inhibition offers a viable additional lipid–lowering option for patients with homozygous familial hypercholesterolemia.

    IMO another nail in the coffin labeled: For HoF patients who fail on Kynamro only. After two years data the supposedly superior drug can't even show for sure any clear-cut CV benefit......much less show that it is superior to Mipo. I would think well-intended lipidologists would reach for Mipo first. Better drug for what you are treating AND a cheaper price. If this were the real world with a high volume medical product a deep discount in the price of juxta would be in order. t

  • jetmanbash by jetmanbash Nov 20, 2014 8:57 AM Flag

    vicl closed yesterday only eleven cents from its yearly low. This with the stock market continuing to mark new highs almost every day. We here at the VNN are attempting to get a list of all employees and help them seek new employment positions once the company does go BK.....except for the CEO who apparently has found a job as a luxury cruise liner captain over in Italy. t

  • jetmanbash jetmanbash Nov 19, 2014 9:05 PM Flag

    I don't think you could hold a candle to bcpiii. t

  • jetmanbash jetmanbash Nov 18, 2014 11:12 PM Flag

    The table shows it all:

    In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO. MACE were defined as myocardial infarction (MI), stroke, unstable angina (UA) and revascularization procedures (PCI/CABG).


    Event
    Number of MACE in
    patients two years prior to
    treatment with KYNAMRO

    Number of MACE in
    patients after two years on
    treatment with KYNAMRO
    MI 39 2
    PCI/CABG 99 6
    UA 5 4
    Stroke 3 0
    Total 146 12

    MACE rate
    (per 1000 patient-months)
    p

  • jetmanbash jetmanbash Nov 18, 2014 10:13 PM Flag

    Part II:
    n this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO. MACE were defined as myocardial infarction (MI), stroke, unstable angina (UA) and revascularization procedures (PCI/CABG).

    Event Number of MACE in
    patients two years prior to
    treatment with KYNAMRO
    Number of MACE in
    patients after two years on
    treatment with KYNAMRO

    MI 39 2
    PCI/CABG 99 6
    UA 5 4
    Stroke 3 0
    Total 146 12

    MACE rate
    (per 1000 patient-months)
    p

  • CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--

    Genzyme, a Sanofi(SNY) company, and Isis Pharmaceuticals Inc.(ISIS) , today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events (MACE) compared to two years prior to therapy.

    “This analysis is very encouraging as the rate of MACE declined sevenfold after two years of treatment with KYNAMRO in patients with homozygous and heterozygous familial hypercholesterolemia (FH),” said Dr. John Kastelein, M.D., Ph.D., professor of medicine, chairman of the department of vascular medicine, Academic Medical Center, University of Amsterdam. “This analysis represents an important finding and supports the potential for further study of the therapeutic benefit of KYNAMRO in patients.”

    This retrospective analysis included 104 patients who enrolled in the long-term extension study of KYNAMRO after having completed one of the KYNAMRO phase 3 blinded, randomized, placebo-controlled 6-month trials in patients with homozygous and heterozygous FH. All patients who completed at least two years of treatment with KYNAMRO were included in the analysis. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO.

  • jetmanbash jetmanbash Nov 16, 2014 11:24 AM Flag

    Agree with you YG. There are so many deals upcoming. One in particular is really secretive for competitive purposes. t

  • Reply to

    Number of LD patients

    by archie_barchie Nov 9, 2014 6:48 PM
    jetmanbash jetmanbash Nov 15, 2014 10:50 AM Flag

    XOMA, and AVNR do look to have some potential in regards to products and high implied volatility. And my favorite ISIS with their ApoCIII drug that lowers triglycerides by 75% and raises good HDL by 55%. Good luck in whatever you do. t

  • Reply to

    Another feather in Mr. Beer's cap:

    by jetmanbash Nov 11, 2014 9:10 PM
    jetmanbash jetmanbash Nov 14, 2014 11:50 AM Flag

    Next move probably will be a shelf offering in order to have some cash to develop and market the new drug. for all of his bragging when the company first started Mr. Beer has certainly made a mess of things IMO. t

  • Reply to

    Very latest press release from RNN:

    by jetmanbash Nov 13, 2014 9:44 AM
    jetmanbash jetmanbash Nov 13, 2014 11:06 AM Flag

    Shareholders will be making more money than you are just talking. t

OGXI
2.10+0.05(+2.44%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST